Pyo Won Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pyo Won Park has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Kiick Sung
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
18 shared publicationsWook Sung Kim
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
17 shared publications- Dong Seop Jeong
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
13 shared publications Young Tak Lee
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
13 shared publications- Kiick Sung
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
12 shared publications Dong Seop Jeong
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
9 shared publications
Latest Publications
- Open Access
- 6 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14  (1) , 1-10
Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis
The increasing use of sodium glucose transporter 2 inhibitors (SGLT2i) for treating cardiovascular (CV) diseases and type 2 diabetes (T2D) is accompanied by a rise in euglycemic diabetic ketoacidosis occurrences in cardiac surgery patients. Patients undergoing cardiac surgery, due to their pre-existing CV disease which often requires SGLT2i prescriptions, face an increased risk of postoperative metabolic acidosis (MA) or ketoacidosis (KA) associated with SGLT2i, compounded by fasting and surgical stress. The primary aim of this study is to quantify the incidence of SGLT2i-related postoperative MA or KA and to identify related risk factors. We analyzed data retrospectively of 823 cardiac surgery patients, including 46 treated with SGLT2i from November 2019 to October 2022. Among 46 final cohorts treated preoperatively with SGLT2i, 29 (63%) developed postoperative metabolic complications. Of these 46 patients, stratified into two categories based on postoperative laboratory findings, risk factor analysis were conducted and compared. Analysis indicated a prescription duration over one week significantly elevated the risk of complications (Unadjusted OR, 11.7; p = 0.032*; Adjusted OR, 31.58; p = 0.014*). A subgroup analysis showed that a cardiopulmonary bypass duration of 60 min or less significantly raises the risk of SGLT2i-related postoperative MA in patients with a sufficient prescription duration. We omitted the term "diabetes" in describing complications related to SGLT2i, as these issues are not exclusive to T2D patients. Awareness of SGLT2i-related postoperative MA or KA can help clinicians distinguish between non-life-threatening conditions and severe causes, thereby preventing unnecessary tests and ensuring best practice.
- 6 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14  (1) , 1-10
Open AccessMissed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis
The increasing use of sodium glucose transporter 2 inhibitors (SGLT2i) for treating cardiovascular (CV) diseases and type 2 diabetes (T2D) is accompanied by a rise in euglycemic diabetic ketoacidosis occurrences in cardiac surgery patients. Patients undergoing cardiac surgery, due to their pre-existing CV disease which often requires SGLT2i prescriptions, face an increased risk of postoperative metabolic acidosis (MA) or ketoacidosis (KA) associated with SGLT2i, compounded by fasting and surgical stress. The primary aim of this study is to quantify the incidence of SGLT2i-related postoperative MA or KA and to identify related risk factors. We analyzed data retrospectively of 823 cardiac surgery patients, including 46 treated with SGLT2i from November 2019 to October 2022. Among 46 final cohorts treated preoperatively with SGLT2i, 29 (63%) developed postoperative metabolic complications. Of these 46 patients, stratified into two categories based on postoperative laboratory findings, risk factor analysis were conducted and compared. Analysis indicated a prescription duration over one week significantly elevated the risk of complications (Unadjusted OR, 11.7; p = 0.032*; Adjusted OR, 31.58; p = 0.014*). A subgroup analysis showed that a cardiopulmonary bypass duration of 60 min or less significantly raises the risk of SGLT2i-related postoperative MA in patients with a sufficient prescription duration. We omitted the term "diabetes" in describing complications related to SGLT2i, as these issues are not exclusive to T2D patients. Awareness of SGLT2i-related postoperative MA or KA can help clinicians distinguish between non-life-threatening conditions and severe causes, thereby preventing unnecessary tests and ensuring best practice.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39  (15) , e143
Outcomes of Concomitant Maze Procedure in Tricuspid Repair for Severe Tricuspid Regurgitation
Park I, et al. J Korean Med Sci. 2024 Apr;39(15):e143. https://doi.org/10.3346/jkms.2024.39.e143
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39  (15) , e143
Open AccessOutcomes of Concomitant Maze Procedure in Tricuspid Repair for Severe Tricuspid Regurgitation
Park I, et al. J Korean Med Sci. 2024 Apr;39(15):e143. https://doi.org/10.3346/jkms.2024.39.e143
- Open Access
- 16 March 2023
- Published by Elsevier in JTCVS Techniques
- Vol. 19, 125-127
Purely bilateral internal thoracic artery bypass grafting in a child with multivessel coronary involvement of Kawasaki disease
- 16 March 2023
- Published by Elsevier in JTCVS Techniques
- Vol. 19, 125-127
Open AccessPurely bilateral internal thoracic artery bypass grafting in a child with multivessel coronary involvement of Kawasaki disease
- Open Access
- 1 June 2021
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 13  (6) , 3359-3368
Reappraisal of mechanical tricuspid valve replacement in the current era: a single center retrospective study
Background: This study aimed to investigate the early and late outcomes of mechanical tricuspid valve replacement (mTVR). Methods: We evaluated 113 patients (82 women; median age, 53 years) who underwent mTVR between 1995 and 2017. Based on a history of cardiac surgery, patients were divided into primary (n=42) and reoperative mTVR (n=71) groups. The median follow-up duration was 12.7 years in primary and 9.3 years in reoperative mTVR, respectively (P=0.045). Results: Patients in the reoperative group were older (54 vs. 46 years; P=0.007) and showed higher central venous pressure (16±6 vs. 13±6 mmHg; P=0.002) than the primary group. Early mortality occurred in 2 patients in the reoperative group (2 vs. 0; P=0.529). There was no significant difference in overall survival between the primary and reoperation groups (15-year survival rate: 86% vs. 78%; P=0.215). The independent risk factors of overall survival were age [Pvs. 60–70 years) in the reoperative group (P=0.772). Tricuspid valve thrombosis occurred in 8 patients (7 primary, 1 reoperative; P=0.004). Conclusions: The incidence of tricuspid valve thrombosis was significantly higher in the primary mTVR group compared with the reoperative mTVR group. The patients who underwent mTVR at a relatively young age showed good early and late outcomes in both groups.
- 1 June 2021
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 13  (6) , 3359-3368
Open AccessReappraisal of mechanical tricuspid valve replacement in the current era: a single center retrospective study
Background: This study aimed to investigate the early and late outcomes of mechanical tricuspid valve replacement (mTVR). Methods: We evaluated 113 patients (82 women; median age, 53 years) who underwent mTVR between 1995 and 2017. Based on a history of cardiac surgery, patients were divided into primary (n=42) and reoperative mTVR (n=71) groups. The median follow-up duration was 12.7 years in primary and 9.3 years in reoperative mTVR, respectively (P=0.045). Results: Patients in the reoperative group were older (54 vs. 46 years; P=0.007) and showed higher central venous pressure (16±6 vs. 13±6 mmHg; P=0.002) than the primary group. Early mortality occurred in 2 patients in the reoperative group (2 vs. 0; P=0.529). There was no significant difference in overall survival between the primary and reoperation groups (15-year survival rate: 86% vs. 78%; P=0.215). The independent risk factors of overall survival were age [Pvs. 60–70 years) in the reoperative group (P=0.772). Tricuspid valve thrombosis occurred in 8 patients (7 primary, 1 reoperative; P=0.004). Conclusions: The incidence of tricuspid valve thrombosis was significantly higher in the primary mTVR group compared with the reoperative mTVR group. The patients who underwent mTVR at a relatively young age showed good early and late outcomes in both groups.
- 1 May 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111  (5) , 1502-1511
Is Prophylactic Tricuspid Annuloplasty Beneficial for Degenerative Mitral Valve Repair?
- 1 May 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111  (5) , 1502-1511
Is Prophylactic Tricuspid Annuloplasty Beneficial for Degenerative Mitral Valve Repair?
- Open Access
- 5 October 2020
- Published by Korean Society for Thoracic and Cardiovascular Surgery in The Korean Journal of Thoracic and Cardiovascular Surgery
- Vol. 53  (5) , 306-309
Left Ventricular Assist Device Implantation via Dual Left Thoracotomy in an Adult Patient with Congenitally Corrected Transposition of the Great Arteries
Shin Kim, M.D., Yang-Hyun Cho, M.D., Pyo Won Park, M.D., Young Tak Lee, M.D., Tae-Gook Jun, M.D., Wook Sung Kim, M.D., Kiick Sung, M.D., Ji-Hyuk Yang, M.D., Suryeun Chung, M.D.. Korean J Thorac Cardiovasc Surg 2020;53:306-9. https://doi.org/10.5090/kjtcs.19.053
- 5 October 2020
- Published by Korean Society for Thoracic and Cardiovascular Surgery in The Korean Journal of Thoracic and Cardiovascular Surgery
- Vol. 53  (5) , 306-309
Open AccessLeft Ventricular Assist Device Implantation via Dual Left Thoracotomy in an Adult Patient with Congenitally Corrected Transposition of the Great Arteries
Shin Kim, M.D., Yang-Hyun Cho, M.D., Pyo Won Park, M.D., Young Tak Lee, M.D., Tae-Gook Jun, M.D., Wook Sung Kim, M.D., Kiick Sung, M.D., Ji-Hyuk Yang, M.D., Suryeun Chung, M.D.. Korean J Thorac Cardiovasc Surg 2020;53:306-9. https://doi.org/10.5090/kjtcs.19.053
- Open Access
- 5 April 2019
- Published by Korean Society for Thoracic and Cardiovascular Surgery in The Korean Journal of Thoracic and Cardiovascular Surgery
- Vol. 52  (2) , 109-111
Late Reoperation Following Ligation of the Left Main Coronary Artery in a Patient with Infective Endocarditis
Dong Woog Yoon, M.D., Sang On Lee, M.D., Pyo Won Park, M.D., Ph.D.. Korean J Thorac Cardiovasc Surg 2019;52:109-11. https://doi.org/10.5090/kjtcs.2019.52.2.109
- 5 April 2019
- Published by Korean Society for Thoracic and Cardiovascular Surgery in The Korean Journal of Thoracic and Cardiovascular Surgery
- Vol. 52  (2) , 109-111
Open AccessLate Reoperation Following Ligation of the Left Main Coronary Artery in a Patient with Infective Endocarditis
Dong Woog Yoon, M.D., Sang On Lee, M.D., Pyo Won Park, M.D., Ph.D.. Korean J Thorac Cardiovasc Surg 2019;52:109-11. https://doi.org/10.5090/kjtcs.2019.52.2.109
- 1 April 2019
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 28  (4) , 647-654
Serial Changes of Transmitral and Transtricuspid Pressure Gradients After Simultaneous Mitral and Tricuspid Ring Annuloplasty
- 1 April 2019
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 28  (4) , 647-654
Serial Changes of Transmitral and Transtricuspid Pressure Gradients After Simultaneous Mitral and Tricuspid Ring Annuloplasty
- 1 November 2018
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 64  (6) , 779-784
Mechanical Surface Area of Prosthetic Heart Valve: Adverse Clinical Impact of Large Mechanical Valve in Mitral Position
Although thromboembolic accidents are serious adverse events associated with mechanical mitral valves, there have been no studies on the clinical impact of the large mechanical surface areas (MSAs) of mechanical mitral prostheses. Between 1995 and 2010, 488 consecutive adult patients underwent isolated mechanical mitral valve replacement. We measured the MSA via three-dimensional computed tomography for each prosthesis. Mean patient age was 50.6 ± 11.1 years. The mean body surface area (BSA) and MSA index (MSAI, MSA/BSA) were 1.6 ± 0.17 m2 and 12.9 ± 1.7 cm2/m2, respectively. The patients were divided into two groups according to the median MSAI. Patients in the high MSAI group had higher indexed left ventricular end-diastolic dimensions and smaller BSAs. The multivariate analysis demonstrated that old age, New York Heart Association class III or IV, and high MSAI were independent predictors of death. With respect to thromboembolic complications, New York Heart Association class III or IV and high MSAI were identified as independent risk factors. There were 11 patients (3%) with mean pressure gradients across the mitral valve greater than 6 mm Hg 1 year after operation. A large MSA relative to patient size was identified as a predictor of poor clinical outcome after mechanical mitral valve replacement.
- 1 November 2018
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 64  (6) , 779-784
Mechanical Surface Area of Prosthetic Heart Valve: Adverse Clinical Impact of Large Mechanical Valve in Mitral Position
Although thromboembolic accidents are serious adverse events associated with mechanical mitral valves, there have been no studies on the clinical impact of the large mechanical surface areas (MSAs) of mechanical mitral prostheses. Between 1995 and 2010, 488 consecutive adult patients underwent isolated mechanical mitral valve replacement. We measured the MSA via three-dimensional computed tomography for each prosthesis. Mean patient age was 50.6 ± 11.1 years. The mean body surface area (BSA) and MSA index (MSAI, MSA/BSA) were 1.6 ± 0.17 m2 and 12.9 ± 1.7 cm2/m2, respectively. The patients were divided into two groups according to the median MSAI. Patients in the high MSAI group had higher indexed left ventricular end-diastolic dimensions and smaller BSAs. The multivariate analysis demonstrated that old age, New York Heart Association class III or IV, and high MSAI were independent predictors of death. With respect to thromboembolic complications, New York Heart Association class III or IV and high MSAI were identified as independent risk factors. There were 11 patients (3%) with mean pressure gradients across the mitral valve greater than 6 mm Hg 1 year after operation. A large MSA relative to patient size was identified as a predictor of poor clinical outcome after mechanical mitral valve replacement.
- 1 June 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10  (6) , 3361-3371
Late clinical outcomes after mechanical aortic valve replacement for aortic stenosis: old versus new prostheses
Background: The study aimed to evaluate the late clinical outcomes of new-generation mechanical valves for severe aortic stenosis (AS) compared with old mechanical valves. Methods: We retrospectively reviewed data from 254 patients with severe AS, who underwent primary mechanical aortic valve replacement from 1995 to 2013. Patients were classified into two groups: old-valve group (n=65: 33 ATS standard, 32 Medtronic-Hall) and new-valve group (n=189: 113 St. Jude Regent, 46 On-X, 30 Sorin Overline). Median patient age was 58 years (Q1–Q3: 52–61). With propensity score matching based on demographic information, 56 patients in the old-valve group were matched with 177 patients in the new-valve group. The median follow-up duration was 91 months (Q1–Q3: 48–138). Results: Cardiac-related mortality and hemorrhagic events were significantly lower in the new-valve group (P=0.047 and P=0.032, respectively). The median international normalized ratio (INR) at follow-up was significantly higher in the old-valve group [2.23, Q1–Q3: 2.14–2.35 (old-valve group); 2.08, Q1–Q3: 1.92–2.23 (new-valve group), PConclusions: New mechanical prostheses showed a better hemodynamic performance and lower incidence of PPM. Anticoagulation strategy to lower the target INR in patients with new mechanical valves may improve late outcomes by reducing hemorrhagic events.
- 1 June 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10  (6) , 3361-3371
Late clinical outcomes after mechanical aortic valve replacement for aortic stenosis: old versus new prostheses
Background: The study aimed to evaluate the late clinical outcomes of new-generation mechanical valves for severe aortic stenosis (AS) compared with old mechanical valves. Methods: We retrospectively reviewed data from 254 patients with severe AS, who underwent primary mechanical aortic valve replacement from 1995 to 2013. Patients were classified into two groups: old-valve group (n=65: 33 ATS standard, 32 Medtronic-Hall) and new-valve group (n=189: 113 St. Jude Regent, 46 On-X, 30 Sorin Overline). Median patient age was 58 years (Q1–Q3: 52–61). With propensity score matching based on demographic information, 56 patients in the old-valve group were matched with 177 patients in the new-valve group. The median follow-up duration was 91 months (Q1–Q3: 48–138). Results: Cardiac-related mortality and hemorrhagic events were significantly lower in the new-valve group (P=0.047 and P=0.032, respectively). The median international normalized ratio (INR) at follow-up was significantly higher in the old-valve group [2.23, Q1–Q3: 2.14–2.35 (old-valve group); 2.08, Q1–Q3: 1.92–2.23 (new-valve group), PConclusions: New mechanical prostheses showed a better hemodynamic performance and lower incidence of PPM. Anticoagulation strategy to lower the target INR in patients with new mechanical valves may improve late outcomes by reducing hemorrhagic events.